Lurasidone hydrochloride for bipolar disorder a review of clinical effectiveness, cost-effectiveness, and guidelines
The aim of this report is to review the comparative clinical effectiveness and cost-effectiveness of lurasidone hydrochloride (as monotherapy or as adjunctive therapy with lithium or valproate) versus other treatments such as typical antipsychotics, other atypical antipsychotics, lithium, lamotrigin...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
February 20, 2020, 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The aim of this report is to review the comparative clinical effectiveness and cost-effectiveness of lurasidone hydrochloride (as monotherapy or as adjunctive therapy with lithium or valproate) versus other treatments such as typical antipsychotics, other atypical antipsychotics, lithium, lamotrigine, antidepressants, valproate, or tryptophan, for the treatment of adults with BD. This report also aims to identify safety-related outcomes and evidence-based guidelines regarding the use of lurasidone hydrochloride for the treatment of adults with BD. |
|---|---|
| Physical Description: | 1 PDF file (32 pages) illustration |